Sheng Yi-Hua, Siemiątkowska Anna, Kosicka-Noworzyń Katarzyna, Brunetti Luigi, Kagan Leonid
Department of Pharmaceutics, Ernest Mario, School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA; Center of Excellence for Pharmaceutical Translational Research and Education, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA.
Department of Pharmaceutics, Ernest Mario, School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA; Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 3 Rokietnicka Street, Poznan 60-806, Poland.
J Pharm Biomed Anal. 2024 Sep 15;248:116259. doi: 10.1016/j.jpba.2024.116259. Epub 2024 Jun 2.
The investigation of drug disposition in tissues is critical to improving dosing strategy and maximizing treatment effectiveness, yet developing a multi-tissue bioanalytical method could be challenging due to the differences among various matrices. Herein, we developed an LC-MS/MS method tailored for the quantitation of piperacillin (PIP), cefazolin (CFZ), and cefoxitin (CFX) in rat plasma and 12 tissues, accompanied by validation data for each matrix according to the FDA and EMA guidelines.
The method required only a small sample volume (5 μL plasma or 50-100 μL tissue homogenates) and a relatively simple protocol for simultaneous quantitation of PIP, CFZ, and CFX within different biological matrices. Mobile phase A was composed of 5 mM ammonium formate and 0.1 % formic acid in water, while mobile phase B contained 0.1 % formic acid in acetonitrile. The mobile phase was pumped through a Synergi Fusion-RP column equipped with a guard column with a gradient elution program at a 0.3 mL/min flow rate. The mass spectrometer was operated in positive ionization mode (ESI+) using multiple reaction monitoring.
The validated method has been successfully applied to quantify PIP, CFZ, and CFX from the plasma and tissue samples collected in a pilot rat study and will further be used in a large pharmacokinetic study. To our knowledge, this is also the first report presenting long-term, freeze-thaw, and autosampler stability data for PIP, CFZ, and CFX in rat plasma and multiple tissues.
研究药物在组织中的处置对于改进给药策略和最大化治疗效果至关重要,然而,由于各种基质之间存在差异,开发一种多组织生物分析方法可能具有挑战性。在此,我们开发了一种液相色谱-串联质谱(LC-MS/MS)方法,用于定量大鼠血浆和12种组织中的哌拉西林(PIP)、头孢唑林(CFZ)和头孢西丁(CFX),并根据美国食品药品监督管理局(FDA)和欧洲药品管理局(EMA)的指南提供了每种基质的验证数据。
该方法仅需少量样品体积(5μL血浆或50 - 100μL组织匀浆),且采用相对简单的方案即可同时定量不同生物基质中的PIP、CFZ和CFX。流动相A由5mM甲酸铵和0.1%甲酸的水溶液组成,流动相B为含0.1%甲酸的乙腈溶液。流动相以0.3mL/min的流速通过配备保护柱的Synergi Fusion-RP柱,采用梯度洗脱程序。质谱仪采用电喷雾电离正离子模式(ESI+),通过多反应监测进行操作。
该经过验证的方法已成功应用于定量在一项大鼠预试验研究中采集的血浆和组织样品中的PIP、CFZ和CFX,并将进一步用于一项大型药代动力学研究。据我们所知,这也是第一份报告大鼠血浆和多种组织中PIP、CFZ和CFX的长期、冻融和自动进样器稳定性数据的研究。